Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 852628 | Other Identifier | University of Pennsylvania IRB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Blood specimens | Collection of blood for analysis of various circulating biomarkers in patients with pancreatic adenocarcinoma. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Obtaining blood for analysis of various circulating biomarkers | Other | 4 tbsp of blood in a 1-week period, occurring no more frequently than 4 times in an 8-week period |
|
| Measure | Description | Time Frame |
|---|---|---|
| To create a comprehensive system to collect, catalogue and store blood specimens from subjects with pancreatic cancer for future research use. | Through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| To create a computerized clinical data set from subjects with pancreatic cancer that contains information related to the subject's general health, disease status, treatments, and response. | Through study completion, an average of 1 year | |
| To integrate the data and specimens to permit the most informative clinical-biologic research platform. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
. Subjects who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.
Not provided
Not provided
Not provided
known or suspected diagnosis of pancreatic adenocarcinoma
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Liudmila Mazaleuskaya, PhD | Contact | 267-455-9141 | mazali@pennmedicine.upenn.edu | |
| Mark O'Hara, MD | Contact | 215-360-0919 | Mark.OHara@pennmedicine.upenn.edu |
| Name | Affiliation | Role |
|---|---|---|
| Mark O'Hara, MD | Abramson Cancer Center, University of Pennsylvania | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Abramson Cancer Center at University of Pennsylvania | Recruiting | Philadelphia | Pennsylvania | 19104 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010190 | Pancreatic Neoplasms |
| ID | Term |
|---|---|
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D004701 | Endocrine Gland Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Through study completion, an average of 1 year |
| D004066 |
| Digestive System Diseases |
| D010182 | Pancreatic Diseases |
| D004700 | Endocrine System Diseases |